Atea Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary

Atea Pharmaceuticals

01/03/2023 02:35

* Atea Pharmaceuticals Inc  AVIR.OQ  reported a quarterly
adjusted
loss of 41 cents​​ per share for the quarter ended in December.
The mean expectation of four analysts for the quarter was for a
loss of 45 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Atea Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 41 cents​.
    * The mean earnings estimate of analysts had risen by
about 0.7%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Atea Pharmaceuticals Inc shares had fallen by 26.0% this
quarter.
    * The company reported a quarterly loss of $34.26 million.
    * Wall Street's median 12-month price target for Atea
Pharmaceuticals Inc is $6.00 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 2
"hold" and 1 "sell" or "strong sell." 

This summary was machine generated from Refinitiv data March 1
at 02:35 a.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.45          -0.41          Beat
 Sep. 30 2022      -0.44          -0.10          Beat
 Jun. 30 2022      -0.52          -0.38          Beat
 Mar. 31 2022      -0.58          -0.51          Beat